Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PLENDIL vs AFEDITAB CR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cells, leading to vasodilation and reduced peripheral vascular resistance.
Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.
Hypertension,Chronic stable angina
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
Initial: 5 mg orally once daily. Maintenance: 2.5–10 mg orally once daily. Maximum: 10 mg/day.
30-60 mg orally once daily, extended-release; maximum 90 mg/day.
Terminal elimination half-life 2-5 hours in healthy adults; 7-12 hours in patients with hepatic impairment or advanced age
Terminal elimination half-life is 6-11 hours; prolonged in hepatic impairment and elderly due to reduced clearance
Primarily hepatic via CYP3A4; undergoes extensive first-pass metabolism.
Primarily hepatic via CYP3A4; undergoes extensive first-pass metabolism.
Renal (approximately 70% as metabolites, <0.5% unchanged); fecal (approximately 10%)
Renal (80% as inactive metabolites), fecal (15% as metabolites), unchanged drug (<1%)
>99% bound, primarily to albumin and alpha1-acid glycoprotein
92-98% bound to plasma proteins (primarily albumin)
4-10 L/kg; large Vd indicates extensive tissue distribution
0.5-0.9 L/kg; high distribution indicates extensive tissue binding
Oral: 15-20% (extensive first-pass metabolism)
Oral extended-release: approximately 50-60% due to first-pass metabolism; absolute bioavailability is 45-60%
No adjustment required for any degree of renal impairment.
No adjustment required for any degree of renal impairment, but use with caution in patients with severe renal failure due to risk of hypotension.
Child-Pugh A or B: Initial dose 2.5 mg orally once daily. Child-Pugh C: Contraindicated or not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Safety and efficacy not established in pediatric patients.
Not recommended for use in pediatric patients; safety and efficacy not established.
Initial dose 2.5 mg orally once daily; titrate cautiously due to increased systemic exposure.
Initiate at lower end of dosing range (30 mg once daily) due to increased sensitivity to hypotensive effects and potential for reduced hepatic clearance.
No FDA black box warning.
No FDA black box warning.
Beta-blocker withdrawal: taper gradually,Peripheral edema,Hepatic impairment,Grapefruit juice increases drug levels
Hypotension, especially with immediate-release formulations,Peripheral edema,Hepatic impairment,Increased angina/acute MI upon withdrawal or dose escalation,Beta-blocker withdrawal,Congestive heart failure
Hypersensitivity to felodipine or any component
Hypersensitivity to nifedipine or any component,Cardiogenic shock,Concomitant use with strong CYP3A4 inducers (e.g., rifampin),Kock pouch (ileostomy)
Avoid grapefruit and grapefruit juice as they increase felodipine plasma concentrations; take on an empty stomach or with a light meal to minimize fluctuations; high-fat meals may increase absorption.
Grapefruit juice increases nifedipine levels via CYP3A4 inhibition; avoid consumption. High-fat meals may delay absorption but do not alter overall exposure. Avoid alcohol as it can exacerbate vasodilation and hypotension.
Pregnancy Category C. First trimester: No adequate studies in humans; animal studies show fetal toxicity at high doses. Second and third trimesters: Potential for fetal hypotension, hypoxia, and growth restriction due to maternal hypotension; avoid use if possible.
Teratogenic effects not established; first trimester: no data in humans, animal studies show no teratogenicity; second and third trimesters: risk of fetal hypoxia, intrauterine growth restriction (IUGR), and oligohydramnios; may cause neonatal hypotension, bradycardia, and hypoglycemia if used near term. Contraindicated in pregnancy for hypertension; use only if benefit outweighs risk (e.g., tocolysis).
Excreted in breast milk; M/P ratio unknown. Insufficient data to determine risk; manufacturer recommends discontinuing nursing or drug due to potential for serious adverse reactions in infant.
Nifedipine excreted into breast milk; M/P ratio approximately 0.42-0.77; limited human data; no adverse effects reported in infants; use with caution during breastfeeding.
Increased clearance of felodipine in pregnancy may necessitate dose adjustments; however, limited data prevent specific recommendations. Use lowest effective dose and monitor clinical response.
Plasma clearance may increase due to higher volume of distribution and metabolism; no specific dose adjustment recommended; titrate based on maternal blood pressure and response; avoid around labor due to tocolytic effect.
Avoid grapefruit products; titrate slowly to minimize reflex tachycardia; use with caution in severe aortic stenosis; may cause peripheral edema, more common in women; administer extended-release tablets whole, do not crush or chew.
AFEDITAB CR is a controlled-release formulation of nifedipine, a dihydropyridine calcium channel blocker. Avoid grapefruit juice as it inhibits CYP3A4 metabolism, increasing nifedipine levels. Use cautiously in patients with aortic stenosis or left ventricular dysfunction due to risk of hypotension. Do not crush or chew tablets; intact shell may appear in stool.
Swallow the tablet whole; do not crush, chew, or split.,Avoid grapefruit juice and grapefruit products while taking this medication.,Do not stop taking suddenly without consulting your physician.,May cause dizziness or lightheadedness; avoid driving if affected.,Report any persistent swelling of ankles or feet, severe dizziness, or irregular heartbeat.
Swallow the tablet whole; do not crush, chew, or break it.,Avoid grapefruit juice while taking this medication.,Do not discontinue abruptly; taper under medical supervision.,Report symptoms of hypotension like dizziness or fainting.,Limit alcohol intake as it may worsen side effects.,Monitor for fluid retention (ankle swelling) and notify doctor if worsening.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PLENDIL vs AFEDITAB CR, answered by our medical review team.
PLENDIL is a Calcium Channel Blocker that works by Dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cells, leading to vasodilation and reduced peripheral vascular resistance.. AFEDITAB CR is a Calcium Channel Blocker that works by Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PLENDIL and AFEDITAB CR depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PLENDIL is: Initial: 5 mg orally once daily. Maintenance: 2.5–10 mg orally once daily. Maximum: 10 mg/day.. The standard adult dose of AFEDITAB CR is: 30-60 mg orally once daily, extended-release; maximum 90 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PLENDIL and AFEDITAB CR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PLENDIL is classified as Category C. Pregnancy Category C. First trimester: No adequate studies in humans; animal studies show fetal toxicity at high doses. Second and third trimesters: Potential for fetal hypotension. AFEDITAB CR is classified as Category C. Teratogenic effects not established; first trimester: no data in humans, animal studies show no teratogenicity; second and third trimesters: risk of fetal hypoxia, intrauterine gro. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.